Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.6.1.1 (
adenylate cyclase
)
19,190
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Morphine inhibits
adenylate cyclase
(
EC 4.6.1.1
) activity of neuroblastoma times glioma hybrid cells. The inhibition is stereospecific and is reversed by the antagonist, naloxone. The relative affinities of narcotics for the opiate receptor agree well with their effectiveness as inhibitors of
adenylate cyclase
. Morphine-sensitive and -insensitive cell lines were found, and the degree of sensitivity was shown to be dependent upon the abundance of narcotic receptors. Thus, morphine receptors are functionally coupled to
adenylate cyclase
. A molecular mechanism for narcotic
addiction
and tolerance is proposed.
...
PMID:Morphine receptors as regulators of adenylate cyclase activity. 105 41
This study describes a novel action of morphine on
adenylate cyclase
activity in the rat locus coeruleus (LC). We have previously shown that acute in vitro morphine inhibits
adenylate cyclase
activity in isolated LC membranes, whereas chronic in vivo morphine treatment increases enzyme activity in this brain region. We now report that acute in vivo morphine treatment produces a 25-30% decrease in
adenylate cyclase
activity in the LC, which persists in in vitro assays in the absence of opiates. This in vivo effect is clearly distinct from the acute inhibition of
adenylate cyclase
observed during exposure of isolated LC membranes to opiates in vitro. The in vivo effect was not reversed by the inclusion of naloxone, an opiate receptor antagonist, in the assay, and acute in vitro opiate inhibition of the enzyme was the same in LC membranes isolated from control and morphine-treated rats. Thus, the in vivo effect does not appear to be due to residual morphine retained in the membrane preparation. This persistent decrease in
adenylate cyclase
was found to occur in a dose-dependent manner and to be mediated through the actions of morphine at opiate receptors, inasmuch as the inhibition was prevented by concomitant in vivo administration of naltrexone, a long-acting opiate receptor antagonist. This effect was also specific to the LC, in that it was not observed in the other brain regions examined, which included the dorsal raphe, neostriatum, and frontal cortex. Acute in vivo clonidine, an alpha 2-adrenergic receptor agonist known to have actions in the LC similar to those of morphine, produced a similar persistent decrease in
adenylate cyclase
activity in this brain region. In contrast, other drugs with different actions on the LC failed to produce this effect. This decrease in
adenylate cyclase
activity induced by acute in vivo morphine or clonidine, which persists in isolated membranes after the removal of the drugs, may be an early step in the sequence of events that leads to the development of opiate or clonidine
addiction
in the LC.
...
PMID:A novel action of morphine in the rat locus coeruleus: persistent decrease in adenylate cyclase. 249 35
A quasi-morphine withdrawal syndrome (QMWS) is a pattern of behavior closely resembling the true withdrawal syndrome in the opiate-dependent animal, which can be elicited acutely by a nonopiate drug in an opiate-naive animal. The main criteria proposed for the QMWS, in addition to its resembling the true withdrawal syndrome, are that the effects of opiates and of opiate antagonists on the QMWS should parallel those on true opiate withdrawal. Drugs that wholly or largely fulfill these criteria are 3-isobutyl-1-methylxanthine (IBMX), theophylline, caffeine, ICI 63197, and RO 201724. From the evidence given, it is concluded that these drugs act by inhibiting brain cyclic AMP phosphodiesterase, thus raising the level of cyclic AMP in appropriate neurons. These findings are consistent with the view that the molecular mechanisms of opiate dependence is the hypertrophy of a neuronal cyclic AMP system in compensation for the inhibition by opiate of an
adenylate cyclase
. Our studies and those of others suggest that: a) very rapid tests for opiate activity and for addictive liability can be devised by use of IBMX; b) opiates may be used clinically to counter poisoning by caffeine or theophylline; and c) a relationship may exist between caffeine consumption and opiate
addiction
.
...
PMID:Character and meaning of quasi-morphine withdrawal phenomena elicited by methylxanthines. 616 62
A possible biochemical vulnerability (trait) marker is examined in a cross-sectional study to determine the biochemical factors associated with the development of alcoholism in a population of non-adult children of alcoholics. The activity of
adenylate cyclase
, an enzyme that plays a role in the signal transduction pathway of several hormones and neurotransmitters, is assessed in blood platelets. This activity was reported to be lower in blood cells of alcoholics and abstinent alcoholics compared with that in controls. In addition, dysregulation of
adenylate cyclase
in the CNS of animals seems to be involved in drug-seeking behaviour. The relation between these biochemical findings and psychopathology is currently being investigated in a project by the Amsterdam Institute for
Addiction
Research.
...
PMID:Adenylate cyclase, a biochemical marker of alcoholism? 784 32
Children of alcoholics have a higher risk of psychopathology and alcoholism. Therefore, in 1993 the Amsterdam Institute for
Addiction
Research initiated a study on vulnerability markers and risk factors in children of alcoholics, aimed at identifying predictors for the development of psychopathology and
addiction
in children of alcoholics. This article provides a summary of the background, rationales and aims of the study. With more specific and sensitive biological vulnerability markers that indicate risk status, more effective preventive interventions might become available. The biochemical part of the study aims at answering the question whether
adenylate cyclase
is a vulnerability marker for alcoholism. The psychophysiological part is directed at event-related potentials during task performance to clarify the nature of the brain and cognitive functions that may underlie or relate to vulnerability to alcoholism. The third part, the psychological component, aims at possible psychological mechanisms of enhanced risk of addition in children of alcoholics as well as the relationship with childhood psychopathology.
...
PMID:Children of alcoholics. Predictors for psychopathology and addiction. 784 37
We have studied the molecular and cellular mechanisms underlying the acute and chronic effects of opiate on neurons of the rat locus coeruleus (LC). Acutely, opiates inhibit LC neurons by activating K+ channels and inhibiting a novel sodium-dependent inward current. Both of these actions are mediated via pertussis toxin-sensitive G-proteins, and regulation of the sodium current occurs through inhibition of the cyclic AMP pathway. In contrast to the acute effects of opiates, chronic treatment of rats with opiates increases levels of specific G-protein subunits,
adenylate cyclase
, cyclic AMP-dependent protein kinase, and a number of phosphoproteins (including tyrosine hydroxylase) in this brain region. Electrophysiological data have provided direct support for the possibility that this upregulation of the cyclic AMP system contributes to opiate tolerance, dependence, and withdrawal exhibited by these noradrenergic LC neurons. As the adaptations in G-proteins and the cyclic AMP system appear to occur at least in part at the level of gene expression, current efforts are aimed at identifying the mechanisms by which opiates regulate the expression of these intracellular messenger proteins in the LC. These studies will lead to an improved understanding of the molecular and cellular basis of opiate
addiction
.
...
PMID:Molecular and cellular mechanisms of opiate action: studies in the rat locus coeruleus. 785 10
We have studied the role of second messenger and protein phosphorylation pathways in mediating changes in neuronal function associated with opiate
addiction
in the rat locus coeruleus. We have found that chronic opiates increase levels of the G-protein subunits Gi alpha and Go alpha,
adenylate cyclase
, cyclic AMP-dependent protein kinase, and a number of phosphoproteins (including tyrosine hydroxylase) in this brain region. Electrophysiological data have provided direct support for the view that this up-regulation of the cyclic AMP system contributes to opiate tolerance, dependence, and withdrawal exhibited by these neurons. As the adaptations in G-proteins and the cyclic AMP system appear to occur at least in part at the level of gene expression, current efforts are aimed at identifying the mechanisms, at the molecular level, by which opiates regulate the expression of these intracellular messenger proteins in the locus coeruleus. These studies will lead to an improved understanding of the biochemical basis of opiate
addiction
.
...
PMID:Second messenger and protein phosphorylation mechanisms underlying opiate addiction: studies in the rat locus coeruleus. 838 77
Prolongation of the action potential duration of dorsal root ganglion (DRG) neurons by low (nM) concentrations of opioids occurs through activation of excitatory opioid receptors that are positively coupled via Gs regulatory protein to
adenylate cyclase
. Previous results suggested GM1 ganglioside to have an essential role in regulating this excitatory response, but not the inhibitory (APD-shortening) response to higher (microM) opioid concentrations. Furthermore, it was proposed that synthesis of GM1 is upregulated by prolonged activation of excitatory opioid receptor functions. To explore this possibility we have utilized cultures of hybrid F11 cells to carry out closely correlated electrophysiological and biochemical analyses of the effects of chronic opioid treatment on a homogeneous population of clonal cells which express many functions characteristic of DRG neurons. We show that chronic opioid exposure of F11 cells does, in fact, result in elevated levels of GM1 as well as cyclic adenosine monophosphate (AMP), concomitant with the onset of opioid excitatory supersensitivity as manifested by naloxone-evoked decreases in voltage-dependent membrane K+ currents. Such elevation of GM1 would be expected to enhance the efficacy of excitatory opioid receptor activation of the Gs/
adenylate cyclase
/cyclic AMP system, thereby providing a positive feedback mechanism that may account for the remarkable supersensitivity of chronic opioid-treated neurons to the excitatory effects of opioid agonists as well as antagonists. These in vitro findings may provide novel insights into the mechanisms underlying naloxone-precipitated withdrawal syndromes and opioid-induced hyperalgesia after chronic opiate
addiction
in vivo.
...
PMID:Chronic opioid treatment of neuroblastoma x dorsal root ganglion neuron hybrid F11 cells results in elevated GM1 ganglioside and cyclic adenosine monophosphate levels and onset of naloxone-evoked decreases in membrane K+ currents. 856 36
The specific participation of protein kinases in the expression of the somatic signs of morphine withdrawal has been previously demonstrated, suggesting that changes in intracellular signalling systems are involved in opioid
addiction
. In the present study, the involvement of protein kinases in the aversive/dysphoric effects of morphine abstinence has been investigated in the nucleus accumbens, because of the critical role played by the mesolimbic system in the rewarding effects of opioids. Rats were chronically treated with morphine, twice a day for 5 days, with doses progressively increased from 5 to 30 mg/kg (i.p.). In addition, microinjections into the nucleus accumbens of the serine-threonine kinase inhibitors H7 or H8 (1 or 10 nmol per side) or saline once daily were also given, both in control and in morphine-treated animals. After these chronic treatments, withdrawal syndrome was induced by naloxone administration (0.1 mg/kg, s.c.), and the motivational component of morphine abstinence was studied using the place aversion paradigm. When administered at the highest dose (10 nmol), H7 and H8 strongly reduced the place aversion induced by naloxone in morphine dependent animals. Protein kinase inhibitors did not induce significant behavioural responses in non-dependent animals. Chronic morphine treatment induced a selective up-regulation of
adenylate cyclase
activity in the amygdala, without affecting other brain regions. The morphine-increased
adenylate cyclase
activity in amygdala was reversed by the chronic intra-accumbens microinjections of H7 and H8. These results suggest that serine-threonine kinases in the nucleus accumbens play an important role in the emotional/dysphoric properties which characterize opiate withdrawal.
...
PMID:Protein kinases in the rat nucleus accumbens are involved in the aversive component of opiate withdrawal. 899 17
To investigate the cellular and molecular basis for using methadone in substitution therapy for morphine
addiction
, the difference between methadone and morphine in causing desensitization of delta-opioid receptors was examined, and the effects of methadone pretreatment on opiate-induced inhibition of forskolin-stimulated cAMP accumulation was studied. Methadone substantially attenuated the ability of [D-Ala2,D-Leu5]enkephalin (DADLE), morphine and methadone to inhibit forskolin-stimulated cAMP accumulation. Methadone was able to block the morphine-induced compensatory increase in intracellular cAMP levels and naloxone-precipitated cAMP overshoot after chronic exposure to morphine. The protein kinase inhibitor (1-5-isoquinolinesulfony)-2-methylpiperazine) (H7) could significantly block the chronic methadone treatment-induced loss of the ability of DADLE to inhibit
adenylate cyclase
. The protein kinase inhibitor chelerythrine was able to block the acute methadone treatment-induced loss of the ability of DADLE to inhibit
adenylate cyclase
. In contrast, morphine did not cause a substantial desensitization of the delta-opioid receptor. These results indicate that methadone is different from morphine in its regulation of the delta-opioid receptor. In addition, these results also indicate that the mechanisms of delta-opioid receptor desensitization induced by acute and chronic methadone treatment are different.
...
PMID:The difference between methadone and morphine in regulation of delta-opioid receptors underlies the antagonistic effect of methadone on morphine-mediated cellular actions. 1041 44
1
2
Next >>